PALO ALTO, Calif., March 25, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced that a presentation titled:
“Synthesis and biochemical characterization of novel analogues of ezatiostat hydrochloride (TLK199, Telintra®)”
will be given at the 102nd annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida. The presentation will be made on Tuesday, April 5th, 2011 from 8:00 am - 12:00 pm in Exhibit Hall A4-C, Poster Section; Cancer Chemistry 8; Abstract # 3246.
About Telik, Inc.
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company’s most advanced drug candidate is Telintra, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome, and Telcyta® a cancer activated prodrug for the treatment of a variety of cancers. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.
SOURCE Telik, Inc.
